Overview

Tolerance, Pharmacokinetics / Pharmacodynamics (PK / PD) and Immunogenicity of Pegylated Uric Acid Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers

Status:
Recruiting

Trial end date:
2023-04-01

Target enrollment:

Participant gender:

Summary

A randomized, double-blind, placebo-controlled study of tolerance, pharmacokinetic / pharmacodynamics (PK / PD) and immunogenicity of single administration of PEG uric oxidase for injection in healthy adults and hyperuricemia volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

The Affiliated Hospital of Qingdao University

Treatments:

Rasburicase